Before taking Mektovi(Binimetinib)

Binimetinib treatment requires careful monitoring for adverse effects, especially liver toxicity and gastrointestinal problems.

Precautions for Binimetinib Tablets

Before initiating treatment with Binimetinib, patients should be assessed for liver function, as the drug may cause hepatic toxicity, which could be severe in some cases. Regular liver function tests are recommended during therapy. Special care should be taken when administering the drug to patients with a history of liver disorders or gastrointestinal conditions, as Binimetinib may cause diarrhea, nausea, or vomiting. Drug interactions should also be considered, particularly with other therapies that affect liver enzymes or the MEK/ERK signaling pathway. Dose adjustments or therapy discontinuation might be necessary if significant toxicity is observed.